Monday, 27 August 2018

Bayer, J&J's bid to further widen use of Xarelto hits snag

Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)